Project Grant HT94252310953
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$841K
Federal Agency
Defense Health Agency
Awardee
Exponent Inc. (F1NXQ68RNFM4)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
West Menlo Park, CA 94025, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $787,890 project grant to The Research Foundation For The State University Of New York (Stony Brook University) to conduct a 3-year study on "MORTALITY RISK FROM EXPOSURE TO BERYLLIUM: EXPOSURE ASSESSMENT AND CO-MORBIDITIES". This grant supports research efforts to investigate the mortality risks associated with beryllium exposure, including assessing exposure levels and...
The Defense Health Agency awarded a $250,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Materion Brush Inc., a division of Materion Corporation, to conduct research on mortality risk and co-morbidities from beryllium exposure over a 3-year period. As a global leader in advanced materials manufacturing, Materion Brush Inc. will leverage its expertise in producing beryllium and beryllium alloys to support innovative medical solutions for service...
The Defense Health Agency awarded a $781,300.00 Project Grant titled "RELATIONSHIP OF METAL EXPOSURES TO HEALTH RISK MARKERS, MOOD, AND COGNITIVE FUNCTIONING IN MILITARY VETERANS" to Trustees of Boston University Medical Campus. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support research to investigate the relationship between metal exposures, health risk indicators, mood, and cognitive functioning in military veterans. Dartmouth...
This federal Project Grant award for $628,292.00, granted by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to investigate military-related toxic exposures as a risk factor for amyotrophic lateral sclerosis (ALS). The award was granted to the Boston VA Research Institute, Inc., a non-profit research organization affiliated with the VA Boston Healthcare System and academic institutions in the Boston area. The project will...
The federal Project Grant award of $1,949,901.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives focused on investigating the relationship between blast exposure and cellular senescence in veterans. The Salisbury Foundation For Research And Education, operating as the Hefner BA Medical Center, will serve as the primary awardee, conducting this research over a...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,309,471 Project Grant to New York University (NYU) School of Medicine to conduct research on the "Genomic and Molecular Imprints of Carcinogenic Benzene Exposure." The project, which spans from September 2024 to September 2027, will investigate the molecular mechanisms and genetic markers associated with benzene exposure and its relationship to cancer development. As a...
The federal Project Grant award of $1,715,075.00 was provided by the Defense Health Agency to Beth Israel Deaconess Medical Center, Inc. (Bidmc) under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research on "The Role of TBI Derived DAMPS in Bacterial Pneumonia" over a period from September 30, 2023 to September 29, 2026. As a major academic medical center and teaching hospital, Bidmc has an extensive portfolio of federal grants and...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $975,210.00 to New York University (NYU) School of Medicine to conduct research on the "Genomic and Molecular Imprints of Carcinogenic Benzene Exposure". The award period runs from September 15, 2024 to September 14, 2027. Through this funding, NYU School of Medicine will carry out innovative biomedical research investigating the genetic and...
The Defense Health Agency awarded Epicentrx Inc. a $385,536 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The project will be conducted over a 3-year period from September 1, 2024 to August 31, 2027. The research aims to transform healthcare for military service members and...
The U.S. Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $325,947 Project Grant to New York University (NYU) School of Medicine on September 15, 2024. The grant supports a 3-year research project titled "Genomic and Molecular Imprints of Carcinogenic Benzene Exposure." This funding enables NYU's research team to investigate the genomic and molecular impacts of benzene exposure, with the goal of advancing scientific...